IMM Chart, page-15

With the Apaic study almost fully enrolled and the ongoing costs of Tacti Mel ,along with the rollout very shortly of Tacti 002 Simon trial ,the cash burn rate will be picking up significantly,you’d imagine. I’m sure the board are onto it ,and for mine perhaps early in the year we will see some form of funding arrangement ,for mine hopefully a upfront payment on a deal done on 761 ,with perhaps Merck ,which ahjay suggested may be a likely candidate.The company has completed the trial ,and has used such terms as exciting and encouraging,re the trial results .We know the data is due shortly ,let’s hope it’s accompanied by some great results and a big upfront payment ,so the company can advance the trials currently taking place and scheduled soon to begin.